Advice
Following Independent Review Panel assessment.
Not recommended for use within NHS Scotland.
Pimecrolimus cream is the first topical immunomodulator licensed for the treatment of signs and symptoms of mild-to-moderate atopic dermatitis. There is no evidence that it has clinical advantage in terms of efficacy or safety when compared with the alternative treatments, which include mild-to-moderately potent topical corticosteroids.
The economic case for using this preparation is unproven.
Download detailed advice28KB (PDF)
Medicine details
- Medicine name:
- pimecrolimus cream (Elidel®)
- SMC ID:
- 35/03
- Indication:
- Mild to moderate atopic dermatitis
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Skin
- Submission type
- IRP
- Status
- Not recommended
- Date advice published
- 09 August 2004
Additional notes